HK1208626A1 - Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof - Google Patents

Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof

Info

Publication number
HK1208626A1
HK1208626A1 HK15109333.0A HK15109333A HK1208626A1 HK 1208626 A1 HK1208626 A1 HK 1208626A1 HK 15109333 A HK15109333 A HK 15109333A HK 1208626 A1 HK1208626 A1 HK 1208626A1
Authority
HK
Hong Kong
Prior art keywords
preparation
long
active ingredient
gel composition
hypoglycemic active
Prior art date
Application number
HK15109333.0A
Other languages
English (en)
Chinese (zh)
Inventor
楊智鈞
呂愛平
卞兆祥
陳曉昱
王芷君
Original Assignee
Univ Hong Kong Baptist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Baptist filed Critical Univ Hong Kong Baptist
Publication of HK1208626A1 publication Critical patent/HK1208626A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15109333.0A 2014-02-19 2015-09-23 Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof HK1208626A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410055853.5A CN104840415B (zh) 2014-02-19 2014-02-19 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法

Publications (1)

Publication Number Publication Date
HK1208626A1 true HK1208626A1 (en) 2016-03-11

Family

ID=53840667

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109333.0A HK1208626A1 (en) 2014-02-19 2015-09-23 Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof

Country Status (5)

Country Link
US (1) US9980906B2 (fr)
JP (1) JP6305555B2 (fr)
CN (1) CN104840415B (fr)
HK (1) HK1208626A1 (fr)
WO (1) WO2015123997A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180169010A1 (en) * 2015-06-16 2018-06-21 Sun Pharma Advanced Research Company Limited Long acting liraglutide compositions
CN108883157A (zh) * 2016-03-31 2018-11-23 太阳医药高级研发有限公司 适用于每周一次或每两周一次给药的利拉鲁肽的粘弹性凝胶
CN106038478B (zh) * 2016-06-24 2019-06-04 天津大学 一种葡萄糖敏感的多孔微球/聚合物复合凝胶及其制备方法和应用
WO2018075822A1 (fr) * 2016-10-19 2018-04-26 Avive, Inc. Nouvelles formulations liposomales pegylées d'apeline pour le traitement de maladies liées au système cardiovasculaire
WO2019126766A1 (fr) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Compositions de triptan à libération prolongée et procédé d'utilisation de celles-ci par voie sous-dermale ou similaire
CN111249472B (zh) * 2020-01-16 2024-02-23 上海交通大学医学院附属第九人民医院 一种可经皮给药的透明质酸纳米凝胶及其制备方法
CN114073666A (zh) * 2020-08-11 2022-02-22 武汉科福新药有限责任公司 纳多洛尔缓释注射剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61501686A (ja) * 1984-02-15 1986-08-14 ザ　リポソ−ム　カンパニ−，インコ−ポレイテツド リポソ−ム↓−ゲル組成物
AU2003282955A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP2006111585A (ja) * 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP3685837A1 (fr) * 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Formulations à libération prolongée à base de supports non aqueux
CN102274182B (zh) 2010-06-13 2013-04-03 上海现代药物制剂工程研究中心有限公司 一种含有艾塞那肽的多囊脂质体及其制备方法和应用
CN102125520A (zh) * 2011-02-24 2011-07-20 美迪思生物科技(北京)有限公司 含亲水性生物大分子的乳剂、其制备方法及用途
CN102198098B (zh) * 2011-06-02 2013-03-27 华东理工大学 温敏性核壳型囊泡控释药物载体、其制备方法及应用
CN102935068B (zh) * 2012-10-19 2014-12-17 浙江海正药业股份有限公司 一种包载水溶性药物的脂质体制备方法

Also Published As

Publication number Publication date
JP6305555B2 (ja) 2018-04-04
US20160074324A1 (en) 2016-03-17
WO2015123997A1 (fr) 2015-08-27
CN104840415B (zh) 2019-03-15
JP2017506256A (ja) 2017-03-02
CN104840415A (zh) 2015-08-19
US9980906B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
HK1255566A1 (zh) 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用
EP3378859A4 (fr) Dérivé du benzofurane, son procédé de préparation et son utilisation en médecine
HK1203317A1 (en) Edible composition, preparation method and use thereof
HK1208626A1 (en) Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof
EP3299369A4 (fr) Composé pyrido-azahétérocyclique, et procédé de préparation et utilisation correspondants
EP3130354A4 (fr) Composition pharmaceutique à base de posaconazole, ainsi que procédé de préparation, utilisation et préparation pharmaceutique de celle-ci
EP3139941A4 (fr) Composition de thé comprenant du cyclocarya paliurus, ainsi que procédé de préparation et utilisations de celle-ci
EP3235494A4 (fr) Préparation transdermique contenant du donépézil comme principe actif
HK1203398A1 (en) Edible composition, preparation method and use thereof
EP3295952A4 (fr) Formulation pharmaceutique comprenant un analogue du glp-1 et son procédé de préparation
SG11201608372PA (en) Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof
EP3373910A4 (fr) Formulation d'échinomycine, procédé de fabrication et méthode d'utilisation de cette dernière
EP3438105A4 (fr) Composé de diaryl-b-lactame et son procédé de préparation et utilisation pharmaceutique associée
EP3225605A4 (fr) Matière active d'interface minérale tk-jh, et procédé de préparation et procédé d'utilisation de celle-ci
EP3181553A4 (fr) Dérivé de quinazoline, procédé pour le préparer, composition pharmaceutique et application de celle-ci
HK1203397A1 (zh) 可食用組合物及其製備方法和用途
EP3395329A4 (fr) Procédé de préparation de corps lipidiques et leur utilisation
EP3241824A4 (fr) Composé d'hydrazide trifluoroacétique ainsi que son procédé de préparation et son application dans la préparation d'un médicament
EP3037099A4 (fr) Composition pharmaceutique, procédé de préparation et utilisation associés
EP3388433A4 (fr) Dérivé de phthalazine et procédé de préparation, composition pharmaceutique et utilisation associées
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EP3243823A4 (fr) Sel de mangiférine-6-o-berbérine, son procédé de préparation et son utilisation
EP3369725A4 (fr) Sel pharmaceutique dérivé de la polyamine, son procédé de préparation et son utilisation
EP2950646A4 (fr) Composition agrochimique, procédé pour sa préparation et utilisation de celle-ci
EP3284743A4 (fr) Composés d'imidazole hétérocycliques, compositions pharmaceutiques les contenant, leur procédé de préparation et utilisation